Product Images Gabapentin

This description appears to be for a medication called Gabapentin with a dosage of 100mg per capsule. The packaging includes details on the lot number, expiration date, and serial number. There is a warning to keep the medication out of reach of children and a suggestion to contact a doctor for advice regarding side effects. The medication should be stored at a controlled temperature of 68-77°F.*

The text provides a table showing the dosage of Gabapentin based on the patient's renal function. The table is divided based on the patient's creatinine clearance, and it indicates the dosage range and regimen for each condition. The text also provides a note for patients with a creatinine clearance of less than 15 ml/min, stating that the daily dose should be reduced proportionally. Additionally, patients undergoing hemodialysis should receive maintenance doses based on estimates of creatinine clearance and a supplemental post-hemodialysis dose administered every four hours. The text also includes abbreviations for dosage regimens.*

This text presents a table that shows the risk of taking antiepileptic drugs compared to taking a placebo. The risks are organized by indication (epilepsy, psychiatric, other, and total) and are measured in events per 1000 patients. The table shows that patients taking antiepileptic drugs had a higher incidence of events compared to those taking a placebo, with relative risks ranging from 15 to 35. Additionally, the table shows the risk difference, which indicates the additional number of drug patients with events per 1000 patients compared to the placebo patients.*

This is a table showing adverse reactions in pooled placebo-controlled trials in postherpetic neuralgia from Gabapentin and Placebo. Adverse reactions were categorized into body as a whole, digestive system, metabolic and nutritional disorders, nervous system, respiratory system, and special senses. The percentage of each adverse reaction is presented alongside the number of participants in each group. Adverse reactions such as asthenia, infection, diarrhea, dizziness, somnolence, ataxia, and abnormal thinking were reported in Gabapentin. Reportedly, blurred vision was observed. However, other adverse reactions such as accidental injury, pharyngitis, and otitis media were observed only in the placebo group.*

This is a list of adverse reactions experienced by epilepsy patients over the age of 12 involved in placebo-controlled add-on trials of Gabapentin. The reactions are listed under various body systems, with the percentages of individuals under Gabapentin and Placebo experiencing them. These include fatigue, increased weight, back pain, dyspepsia, somnolence, dizziness, pharyngitis, and others. Amblyopia, which was often described as blurred vision, occurred more frequently under Gabapentin compared to Placebo.*

This is a table showing the adverse reactions observed in a clinical trial comparing Gabapentin® to placebo as an add-on treatment in pediatric epilepsy patients aged 3 to 12 years. The table compares the percentage of adverse reactions observed in two groups of patients, N=110 for Gabapentin® and N=128 for Placebo. Adverse reactions observed in the Gabapentin® group include increased weight, fatigue, nausea and/or vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis, and respiratory infection. Adverse reactions observed in the placebo group include body aches and flu-like symptoms, fever, nausea and/or vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis, and respiratory infection. Additionally, both groups were receiving background antiepileptic drug therapy.*

This text provides a table showing the duration, dosages, and number of patients involved in two controlled studies of PHN treated with Gabapentin. Study 1 lasted 8 weeks and involved 113 patients receiving 3600mg/day of Gabapentin and 116 receiving Placebo. Study 2 lasted 7 weeks and involved 223 patients receiving either 1800mg/day or 2400mg/day of Gabapentin, and 11 patients receiving placebo. The total number of patients was 227 and the dosages were given in 3 divided doses (TID).*

The text appears to be a figure caption showing the proportion of responders in controlled studies for PHN. The figure shows Study 1 and Study 2 with a proportion of 34% and controlled groups with different dosages of medication. As the text doesn't provide a comprehensive description of the studies, it might not be possible to interpret the results without referring to the corresponding research article.*